Figure 4From: Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial Worst-case (left) and nominal (right) dose-distribution plans for the patient whose local recurrence appeared outside the 60 Gy(RBE) (red) isodose lines on both set of plans. Back to article page